Idiopathic Pulmonary Arterial Hypertension Clinical Trial
Official title:
Clinical and Mechanistic Understanding of Right Ventricular Steatosis in Pulmonary Arterial Hypertension (PAH)
The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of lipid accumulation.
The investigators propose to test the hypothesis that abnormal lipid metabolism in PAH leads to delivery of fatty acids in excess of RV oxidative capacity, resulting in steatosis and lipotoxicity. The objectives of the study are to: 1) Define the relationships between RV steatosis, RV function, and exercise capacity; 2) Identify mechanistic drivers of RV steatosis including BMPR2 expression and lipid metabolism; 3) Examine lipid metabolism in PAH skeletal muscle as a potential driver of reduced functional capacity. In Aim 1 (clinical relevance) the investigators will measure RV and left ventricle (LV) lipid in participants with heritable, idiopathic, and scleroderma- associated PAH. Participants will undergo the 6-minute walk test, cardiopulmonary exercise testing, and will be followed for clinical events. A subgroup will undergo repeat MRS at four timepoints over three years to determine the natural history of steatosis. In Aim 2 (mechanism), the investigators will perform metabolomic/lipidomic profiling of peripheral and coronary sinus plasma and measure BMPR2 expression to identify potential drivers of steatosis. In Aim 3 (specificity), the investigators will perform MRS on skeletal muscle in Aim 1 participants and matched healthy controls to clarify the systemic effects of lipid metabolic defects in PAH. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01884051 -
Hormonal, Metabolic, and Signaling Interactions in PAH
|
||
Completed |
NCT00626028 -
Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
|
Phase 3 | |
Completed |
NCT02790450 -
Acute Effects of Benzbromaron on the Pulmonary Circulation
|
Phase 2 | |
Recruiting |
NCT05584722 -
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
|
||
Completed |
NCT01590108 -
The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05493371 -
Empagliflozin in Pulmonary Arterial Hypertension
|
Phase 2 | |
Recruiting |
NCT03933579 -
The PAH Platform for Deep Phenotyping in Korean Subjects
|
||
Completed |
NCT01613287 -
Proof of Concept Study of IMMUNOadsorption Therapy in Patients With Idiopathic Pulmonary Arterial Hypertension
|
N/A | |
Recruiting |
NCT00372346 -
Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension
|
N/A | |
Withdrawn |
NCT01645826 -
Efficacy Study of Cardizem in Pulmonary Arterial Hypertension
|
N/A | |
Completed |
NCT00641836 -
Safety and Feasibility of Autologous Endothelial Progenitor Cells Transplantation in Patients With Idiopathic Pulmonary Arterial Hypertension
|
N/A | |
Not yet recruiting |
NCT06104228 -
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
|
Phase 2 | |
Recruiting |
NCT02959723 -
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies
|
N/A | |
Recruiting |
NCT01288651 -
Iron Deficiency In Pulmonary Hypertension
|
Phase 4 | |
Completed |
NCT02565030 -
Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome
|
||
Active, not recruiting |
NCT01246037 -
Beta-blockers in i-PAH
|
Phase 1/Phase 2 | |
Recruiting |
NCT01683981 -
Exercise Capacity and Quality of Life in Patients With PPH Receiving Short Term Oral L-Citrulline Malate
|
Phase 0 | |
Completed |
NCT03069716 -
A Mobile Health Intervention in Pulmonary Arterial Hypertension
|
N/A | |
Completed |
NCT05767918 -
StratosPHere (Non-interventional Study)
|
||
Completed |
NCT00257413 -
Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension
|
N/A |